Chief Medical Officer

Ulo Palm, MD

Ulo has 30 years of experience in pharmaceutical R&D in a range of clinical, operational, and quality functions. He was recognized by CenterWatch as one of 20 innovators changing the face of the clinical trials industry and by The Medicine Maker as one of the 100 most influential people in clinical trials in 2015. Over the course of his career, Ulo has contributed to 30+ successful New Drug Applications (NDAs) in major therapeutic areas and has led strategy development and implementation of new, groundbreaking technologies in clinical research. Before joining Vaxxinity, he was co-founder and CMO at Ordaos Bio, an AI drug design company with the mission of using digital sciences, machine learning, and AI to increase the speed and efficacy of drug R&D. Prior to Ordaos, Ulo was SVP at Allergan where he led Digital Sciences and Global Drug Development Operations.  Ulo’s preceding roles include SVP of Clinical Operations & Biometrics and Therapeutic Area Head of Respiratory Clinical Development with Forest Labs; Global Head, Laboratory & Preclinical Quality Assurance and Global Head of Clinical Operations Oncology with Novartis; and various drug development roles at Schering-Plough and Bayer. He has also been the past Chair of the Oversight Committee and Corporate Secretary of TransCelerate BioPharma, a nonprofit organization formed by the top 20 global biopharmaceutical companies to collaborate in modernizing clinical research globally and accelerate the development of new efficient, effective, and high-quality new medicines. He is a Senior Member of the American Society for Quality and a certified Manager of Quality and Organizational Excellence. His work at the ASQ includes initiating and co-authoring the ASQ report on “Best Quality Practices For Biomedical Research In Drug Development”. Ulo earned his MD and PhD from the Free University of Berlin and a MBA from the AKAD University of Applied Sciences in Rendsburg, Germany.